Mirus Bio
- Company typePrivate
- Founded1995
- HeadquartersMadison, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Mirus Bio firmographics
Firmographics- Name
- Mirus Bio
- Legal name
- Mirus Bio LLC
- Website
- https://mirusbio.com
- Company type
- Private
- Founded year
- 1995
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Mirus Bio industry classification
Industry- Product category
- Life Sciences Transfection Reagents
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)
- akta.pro secondary industries
- Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)
Keywords
Where Mirus Bio is headquartered
LocationHeadquarters
- HQ city
- Madison
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Mirus Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Transfection Reagent Sales: Sale of transfection reagents and kits for nucleic acid delivery in discovery research, viral vector production, and protein production applications. Products include TransIT, VirusGEN, and CHOgro product lines sold in various sizes from research-scale (0.3mL) to manufacturing-scale (150mL).
- GMP Product Sales: Sale of GMP-grade transfection reagents and enhancers for clinical and commercial cell and gene therapy manufacturing. GMP products command premium pricing and include regulatory support packages, drug master files, and quality documentation for regulatory filings.
- AAV Enhancer and Stabilizer Products: Specialty additives including RevIT AAV Enhancer and VirusGEN/AAViator Stabilizers that enhance viral vector production yields. Sold as standalone products or bundled in transfection kits at various scales.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Discovery Research Reagents - Small volume transfection reagents for laboratory research applications |
| Unit Pricing | Pay-as-you-go | Virus Production Reagents - Transfection reagents for viral vector manufacturing at various scales |
| Unit Pricing | Pay-as-you-go | RevIT AAV Enhancer - Titer enhancement additive for AAV production |
| Unit Pricing | Multi-year contract | AAViator Transfection System - Next-generation AAV production platform |
| Unit Pricing | Pay-as-you-go | Protein Production Systems - CHOgro and TransIT-PRO for recombinant protein expression |
| Unit Pricing | Multi-year contract | GMP Products - Clinical and commercial manufacturing grade reagents |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
Mirus Bio product offering
Product offeringCore offering
Mirus Bio develops, manufactures, and commercializes nucleic acid transfection reagents and systems used in life science research and biopharmaceutical manufacturing. Its products enable the delivery of DNA, mRNA, siRNA, and other nucleic acids into eukaryotic cells for applications spanning discovery research, viral vector (AAV and lentivirus) production for cell and gene therapies, and recombinant protein/antibody manufacturing in CHO cells. The portfolio includes research-use-only (RUO) and GMP-grade reagent lines such as TransIT, VirusGEN, AAViator, RevIT, CHOgro, and Ingenio.
Product overview
Mirus Bio offers a comprehensive portfolio of transfection reagents and systems for nucleic acid delivery across discovery research, cell and gene therapy manufacturing, and protein production applications. The core product lines include: (1) Discovery Research products (TransIT-X2, TransIT-mRNA, TransIT-2020, TransIT-LT1, TransIT-TKO, TransIT-siQUEST, TransIT-Oligo, TransIT-HeLaMONSTER, Ingenio electroporation) for CRISPR, mRNA, siRNA, and DNA delivery; (2) Cell and Gene Therapy products (TransIT-VirusGEN, TransIT-AAViator, RevIT AAV Enhancer, AAViator Stabilizer, VirusGEN Stabilizer) for AAV and lentivirus production at research and GMP scales; (3) Protein Production products (TransIT-PRO, CHOgro High Yield Expression System) for recombinant protein and antibody manufacturing. Products are available in both RUO (Research Use Only) and GMP quality grades, with GMP products manufactured in ISO 13485 certified facilities for clinical and commercial bioprocessing.
Differentiator
Problem solved
Functional benefit
Brands
- TransIT: Transfection reagent product line for nucleic acid delivery across discovery research, virus production, and protein production applications.
- VirusGEN
- AAViator
- RevIT
- CHOgro
- Ingenio
- Label IT
Products and services
- TransIT-X2 Dynamic Delivery System A polymeric transfection reagent for delivering multiple nucleic acids (DNA, guide RNA, Cas9 RNP formats) into mammalian cells for CRISPR/Cas9 genome editing and other research applications.
- TransIT-mRNA Transfection Kit A high-efficiency, low-toxicity transfection reagent for delivering mRNA, including Cas9 mRNA and guide RNA, into mammalian cells for research and CRISPR applications.
- TransIT-2020 Transfection Reagent An animal-free, broad-spectrum DNA transfection reagent that achieves high expression in many cell types, including hard-to-transfect lines, with low cellular toxicity.
- TransIT-LT1 Transfection Reagent A low-toxicity, broad-spectrum DNA transfection reagent that maintains cell density while achieving high-efficiency delivery across many cell types.
- TransIT-TKO Transfection Reagent A transfection reagent optimized for siRNA and miRNA delivery into mammalian cells for gene silencing applications.
- TransIT-siQUEST Transfection Reagent A transfection reagent for siRNA and miRNA delivery in mammalian cells for gene silencing research.
- TransIT-Oligo Transfection Reagent A transfection reagent optimized for delivery of oligonucleotides to mammalian cells for research applications.
- TransIT-HeLaMONSTER Transfection Kit A cell-specific DNA transfection reagent optimized for HeLa cells, providing high efficiency with low toxicity.
- Ingenio EZporator Electroporation System An easy-to-use electroporation system for nucleic acid delivery into mammalian cells, including hard-to-transfect cells, compatible with Lonza-Amaxa, Bio-Rad, and Harvard BTX devices.
- Label IT Nucleic Acid Labeling Kit A kit for modifying and labeling nucleic acids, supporting research applications including CRISPR cell enrichment.
- TransIT-VirusGEN Transfection Reagent A transfection reagent designed for enhanced delivery of packaging and transfer plasmids into HEK 293 cells to increase recombinant AAV and lentivirus production for cell and gene therapy manufacturing.
- TransIT-AAViator Transfection System A next-generation transfection system specifically designed for maximal AAV production, combining polymer and lipid chemistry to deliver higher titers and reduced plasmid DNA consumption at scales from 1.5L to 200L.
- RevIT AAV Enhancer An AAV titer enhancer that delivers a 2-4x increase in AAV titers across multiple serotypes, cell lines, growth media, and transfection reagents while reducing plasmid DNA requirements.
- AAViator Stabilizer A transfection complex stabilizer for the AAViator system that extends complex formation time to 3 hours and reduces complex volume by more than 50% while maintaining high titers.
- VirusGEN Transfection Complex Stabilizer An additive used with TransIT-VirusGEN and RevIT AAV Enhancer to stabilize transfection complexes for 3 hours and reduce complex volume to 2% of culture volume for scalable AAV and lentivirus production.
- VirusGEN AAV Transfection Kit A complete kit for AAV production including TransIT-VirusGEN reagent, RevIT enhancer, stabilizer, and protocols for research and process development using adherent or suspension HEK 293 cells.
- VirusGEN LV Transfection Kit A complete kit for lentivirus production including TransIT-VirusGEN reagent, protocols, and support for suspension cell cultures.
- TransIT-VirusGEN GMP Transfection Reagent GMP-grade transfection reagent for large-scale therapeutic AAV and lentivirus production, manufactured in ISO 13485 certified facilities and including regulatory support packages for clinical and commercial bioprocessing.
- TransIT-AAViator GMP Transfection System A GMP-grade transfection system for maximal AAV production at clinical and commercial scales, including TransIT-AAViator GMP reagent and RevIT GMP enhancer.
- RevIT GMP AAV Enhancer GMP-grade AAV titer enhancer for clinical and commercial manufacturing, providing 2-4x titer increases with reduced DNA requirements.
- VirusGEN GMP Transfection Complex Stabilizer GMP-grade transfection complex stabilizer for late-stage development and manufacturing, with release testing aligned with ISO 20399 and USP <1043> standards.
- TransIT-PRO Transfection Reagent A transfection reagent for protein and monoclonal antibody production in CHO and 293 cells, providing high protein yields in suspension culture.
- CHOgro High Yield Expression System A complete system for high-yield recombinant protein and antibody production from suspension CHO cells, including expression medium, complex formation solution, TransIT-PRO transfection reagent, and titer enhancer.
Quantifiable outcome
- 2-4X increase in AAV titers with RevIT AAV Enhancer across multiple serotypes, cell lines, and media
- +5 more outcomes
Companies that use Mirus Bio
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Mirus Bio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Mirus Bio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and flagship.
- Transfection Adoption Partnership (TAP) Program MemberscorePartnership program for AAV manufacturing companies providing preferred pricing, priority white-glove service, and thought leadership opportunities. Members receive tailored support to enhance transfection processes and access to exclusive benefits including process optimization assistance.
- KytopencoreCollaboration to combine industry-leading technologies and tackle non-viral delivery of highly complex genome engineering materials to help create next-generation living medicines. The partnership leverages Mirus Bio's transfection expertise with Kytopen's flow electroporation technology.
- Gamma BiosciencesflagshipEntered into strategic investment partnership with Gamma Biosciences, a global life sciences company serving the advanced therapy market established by KKR. Gamma Biosciences provided capital and strategic support for Mirus Bio's growth and GMP expansion initiatives prior to the Merck KGaA acquisition.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Mirus Bio competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Global CDMO with significant viral vector and cell therapy manufacturing capabilities. Comparable as a large incumbent serving the gene therapy bioprocessing market where Mirus's reagents are consumed, though Lonza is a service provider rather than a reagent supplier.
- Thermo Fisher Scientific: Diversified life sciences leader that supplies transfection reagents (lipofectamine portfolio), cell culture media, and viral vector CDMO services. Direct overlap with Mirus in nucleic acid delivery reagents for gene therapy manufacturing and research.
- Catalent (Paragon BioServices): Major gene therapy CDMO with viral vector manufacturing capabilities (acquired Paragon). Comparable customer base (gene therapy developers needing high-yield AAV production) where Mirus's transfection reagents compete against integrated Catalent workflows.
- Cytiva: Provider of bioprocessing tools, equipment, and consumables for cell and gene therapy manufacturing. Comparable as a broader bioprocessing incumbent whose upstream processing products compete with elements of Mirus's transfection and enhancer portfolio.
Direct peers
- Bio-Techne: Develops and sells reagents for cell and gene therapy workflows including transfection reagents under the Trevigen and ProteinSimple brands. Direct competitor in transfection and gene delivery reagents serving similar research and bioprocessing customers.
- Polysciences: Long-standing transfection reagent manufacturer offering PEI-based and other polymer reagents widely used for viral vector production. Direct product overlap with Mirus in the AAV/lentiviral manufacturing reagent market.
- Takara Bio: Japanese life sciences company offering transfection reagents (Lipofectamine competitors), gene therapy tools, and viral vector production services. Direct overlap with Mirus in nucleic acid delivery reagents and serves similar Asian biopharma customers.
Emerging players
- MaxCyte: Electroporation-based transfection technology company with growing presence in cell therapy manufacturing. Comparable as a non-viral delivery platform for gene editing and cell engineering, with potential overlap through the Kytopen partnership on Mirus's side.
- Aldevron: Manufacturer of plasmid DNA, proteins, and other critical inputs for cell and gene therapy manufacturing. Comparable as a key supplier of ancillary raw materials to AAV/lentiviral producers where Mirus's transfection reagents are consumed together with Aldevron's plasmids.
- GenScript: Life sciences tools and services company offering gene synthesis, cell therapy reagents, and viral vector production services. Partial overlap with Mirus in nucleic acid delivery and protein expression tools serving biotech customers.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Mirus Bio social profiles
Digital presenceMirus Bio compliance and trust
Trust signalCompliance3 records
Mirus Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mirus Bio leadership team
Management profileNumber of profiles
Profiles7 records
Mirus Bio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mirus Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mirus Bio
What does Mirus Bio do?
Mirus Bio develops, manufactures, and commercializes nucleic acid transfection reagents and systems used in life science research and biopharmaceutical manufacturing. Its products enable the delivery of DNA, mRNA, siRNA, and other nucleic acids into eukaryotic cells for applications spanning discovery research, viral vector (AAV and lentivirus) production for cell and gene therapies, and recombinant protein/antibody manufacturing in CHO cells. The portfolio includes research-use-only (RUO) and GMP-grade reagent lines such as TransIT, VirusGEN, AAViator, RevIT, CHOgro, and Ingenio.
Is Mirus Bio a public or private company?
Mirus Bio is a private company. It is classified as corporate owned and is currently operating.
When was Mirus Bio founded?
Mirus Bio was founded in 1995. It employs 11 to 50 people.
Where is Mirus Bio based?
Mirus Bio is headquartered in Madison, United States, in the North America region.
How does Mirus Bio make money?
Three revenue lines are on record. Transfection Reagent Sales are the primary driver. The others are GMP Product Sales and AAV Enhancer and Stabilizer Products.
Who are Mirus Bio's main competitors?
Broad incumbents on record are Lonza Group, Thermo Fisher Scientific, Catalent (Paragon BioServices) and Cytiva. Direct peers are Bio-Techne, Polysciences and Takara Bio. Emerging players are MaxCyte, Aldevron and GenScript.
Does Mirus Bio have an API?
No public API is recorded for Mirus Bio.
What industry is Mirus Bio in?
Mirus Bio's product category is Life Sciences Transfection Reagents. Its primary akta.pro industry code is HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services, with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 325414 and its SIC code is 2836.